Ayala Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ayala Pharmaceuticals stock.
View analyst ratings for Ayala Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ayala Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ayala Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ayala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Ayala Pharmaceuticals.

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.04. The business had revenue of $0.66 million for the quarter, compared to the consensus estimate of $1.05 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 625.24% and a negative net margin of 850.81%.
View Ayala Pharmaceuticals' earnings history.

6 brokers have issued 12 month price targets for Ayala Pharmaceuticals' stock. Their forecasts range from $20.00 to $29.00. On average, they expect Ayala Pharmaceuticals' share price to reach $24.20 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for Ayala Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ayala Pharmaceuticals include Orchard Therapeutics (ORTX), Osiris Therapeutics (OSIR), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), Agenus (AGEN), Precision BioSciences (DTIL), DBV Technologies (DBVT), Jounce Therapeutics (JNCE), Solid Biosciences (SLDB), Compugen (CGEN), MeiraGTx (MGTX), Curis (CRIS), Oyster Point Pharma (OYST), Poseida Therapeutics (PSTX) and Gritstone Oncology (GRTS).
View all of AYLA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Square (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

(AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AYLA stock can currently be purchased for approximately $13.41.

Ayala Pharmaceuticals has a market capitalization of $171.37 million and generates $2.33 million in revenue each year.

Ayala Pharmaceuticals employs 31 workers across the globe.

The official website for Ayala Pharmaceuticals is www.ayalapharma.com.

Ayala Pharmaceuticals is headquartered at Oppenheimer 4, Rehovot L3, 7670104.

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 857-444-0553 or via email at [email protected]